Two Cases of Capecitabine-Induced Ileitis in Patients Treated with Radiochemotherapy to the Pelvis and Review of the Literature

Mohiuddin M, Marks J, Marks G. Management of rectal cancer: short vs. long-course preoperative radiation. Int J Radiat Oncol Biol Phys. 2008;72:636. Kim JS, Kim JS, Cho MJ, Song KS, Yoon WH. Preoperative chemoradiation using oral capecitabine in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2002;54:403. Saif MW, Katirtzoglou NA, Syrigos KN. Capecitabine: an overview of the side effects and their management. Anti-Cancer Drugs. 2008;19:447–64. Al-Gahmi AM, Kerr IG, Zekri JM, Zagnoon AA. Capecitabine-induced terminal ileitis. Ann Saudi Med. 2012;32:661–2. Mokrim M, Aftimos PG, Errihani H, Piccart-Gebhart M. Breast cancer, DPYD mutations and capecitabine-related ileitis: description of two cases and a review of the literature. BMJ Case Rep. 2014; doi:10.1136/bcr-2014-203647. Radwan R, Namelo WC, Robinson M, Brewster AE, Williams GL. Ileitis secondary to oral capecitabine treatment? Case Rep Med. 2012;2012:154981. Bouma G, Imholz AL. Ileitis following capecitabine use Nederlands Tijdschrift voor Geneeskunde, vol. 155, article A3064, 2011. Lee SF, Chiang CL, Lee AS, Wong FC, Tung SY. Severe ileitis associated with capecitabine: two case reports and review of the literature. Mol Clin Oncol. 2015;3(6):1398–400. Barton D. Ulcerative ileitis secondary to adjuvant capecitabine for colon cancer: a case report. (UICC world Cancer Congress 2006). Arbea L, Ramos LI, Martínez-Monge R, Moreno M, Aristu J. Intensity-modulated radiation therapy (IMRT) vs. 3D conformal radiotherapy (3DCRT) in locally advanced rectal cancer (LARC): dosimetric comparison and clinical implications. Radiat Oncol. 2010;5:17. Zhao J, Hu W, Cai G, Wang J, Xie J, Peng J, et al. Dosimetric comparisons of VMAT, IMRT and 3DCRT for locally advanced rectal cancer with simultaneous integrated boost. Oncotarget. 2016;7(5):6345–51. Zhu J, Liu F, Weilie G, Lian P, Sheng W, Xu J, et al. Concomitant boost IMRT-based neoadjuvant chemoradiotherapy for clinical stage II/III rectal adenocarcinoma: results of a phase II study. Radiat Oncol. 2014;9:70. doi:10.1186/1748-717X-9-70.